Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05426018
Other study ID # SY009003
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 1, 2022
Est. completion date October 1, 2023

Study information

Verified date May 2022
Source Suzhou Yabao Pharmaceutical R&D Co., Ltd.
Contact Dalong Zhu, DR
Phone 13805150781
Email zhudalong@nju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SY-009 is a novel compound that inhibits sodium glucose cotransporter-1 (SGLT-1). The preclinical and phase 1 clinical trial data support to carry out phase II clinical trial in diabetes subjects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date October 1, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Subjects were = 18 years old and = 75 years old at the first screening (visit 1); 2. At the first screening (visit 1) and the baseline period (visit 3), male weight = 50kg, female weight = 45kg, and body mass index (BMI) between 18.0 and 35.0 kg/m2 (including the critical value); 3. At the first screening (visit 1), the subjects had been diagnosed with type 2 diabetes for at least 3 months according to the WHO diagnostic criteria and classification in 1999; 4. The subjects had been receiving diet control and exercise therapy for 3 months before the first screening (visit 1), and had not received systematic treatment for diabetes during this period (the cumulative use of hypoglycemic drugs in recent 3 months was not more than 2 weeks, and no hypoglycemic drugs were used in recent 1 month); 5. The subjects' HbA1c at the first screening (visit 1) was between 7.5% and 10.5% (including the critical value); During the baseline period (visit 3), HbA1c was between 7.0% and 10.5% (including the critical value); 6. Subjects' fasting blood glucose = 13.3mmol/l in the baseline period (visit 3); 7. Before the trial, the nature, significance, possible benefits, possible inconvenience, potential risks and discomfort of the trial have been understood in detail, and they have volunteered to participate in the clinical trial. They can communicate well with researchers, comply with the requirements of the whole trial, and have signed a written informed consent. Exclusion Criteria: 1. Known allergic to the test drug (including the excipients of the test drug) or its analogues, or allergic constitution (such as allergic to two or more drugs, food and pollen), or having taken SGLT-1 or sglt-2 inhibitors in the past 1 year; 2. Received long-term (>2 weeks) systemic glucocorticoid therapy (excluding topical, ophthalmic or inhaled preparations) within 3 months before screening; 3. Diagnosed as type 1 diabetes, or gestational diabetes, or other special types of diabetes; 4. There is sufficient evidence of active diabetes proliferative retinopathy; 5. History of severe hypoglycemia (such as consciousness disorder and coma caused by hypoglycemia), or history of serious unconscious hypoglycemia; 6. History of acute metabolic complications of diabetes within 6 months before screening (diabetes ketoacidosis, hypertonic non ketoacidosis coma, diabetes lactic acidosis); 7. Serious trauma, serious infection or operation that may affect blood glucose control occurred within 1 month before screening; 8. There are obvious blood system diseases (such as aplastic anemia, myelodysplastic syndrome), or any disease that causes hemolysis or red blood cell instability (such as malaria), or hemoglobinopathy that may affect the determination of HbA1c level (such as sickle cell disease); 9. Have obvious autonomic neuropathy, such as urinary retention, postural hypotension, diabetes diarrhea or gastroparesis; 10. Habitual diarrhea, irritable bowel syndrome, clinically significant abnormal gastric emptying (such as gastric outlet obstruction), severe chronic gastrointestinal diseases (such as active ulcer within 6 months) or gastrointestinal surgery within 3 months before screening; 11. History of organ transplantation (excluding corneal transplantation), or other acquired or congenital immune system diseases, or clinically significant peripheral vascular diseases; 12. History of heart failure (NYHA grade III and IV), or history of acute myocardial infarction or unstable angina pectoris within 6 months before screening; Or have a history of coronary angioplasty, coronary stent implantation or coronary artery bypass surgery within 6 months before screening or have a recent cardiac surgery plan; 13. In the screening period, when no pacemaker was installed, grade II or III atrioventricular block or qtcb interval was prolonged >500 MS in 12 lead ECG; 14. Patients with abnormal thyroid function (such as thiourea and thyroid hormone drugs) whose treatment dose was not stable within the first 6 months were screened; Hypothyroidism with poor control or history of hypothyroidism; 15. Unstable weight (weight change more than 5kg) within 2 months before screening, or used drugs with weight control effect or performed surgery that can lead to unstable weight, or is currently in the weight loss plan and is not in the maintenance stage; 16. Poor blood pressure control (systolic blood pressure (SBP) = 160mmhg and / or diastolic blood pressure (DBP) = 100 mmHg); 17. At the first screening (visit 1), the subjects were positive for HBsAg, HCV antibody, Treponema pallidum antibody or human immunodeficiency virus antibody; 18. The clinical laboratory test results at the first screening (visit 1) and the baseline period (visit 3) meet any of the following criteria: 1) Hemoglobin (Hgb) < 100g/l; 2) Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2 times the upper limit of normal value (ULN);3) Total bilirubin (TBIL) > 1.5 times the upper limit of normal value (except for the known Gilbert syndrome that meets the following requirements, that is, part of bilirubin indicates conjugated bilirubin < 35% of total bilirubin); 4) Triglyceride (TG) = 5.7mmol/l; 5) Estimated glomerular filtration rate < 60 ml/min (estimated by CKD-EPI formula); 19. Regular drinking (weekly alcohol intake greater than 21 units (male) and 14 units / week (female) (1 unit = 360ml beer; 150ml wine; or 45ml Baijiu) within 3 months before screening, or unable to quit drinking during the test; 20. Those who lost more than 400 ml of blood / donated blood (except physiological blood loss of women) within 3 months before screening, received blood transfusion or used blood products, or planned to donate blood during the test or within 1 month (30 days) after the end of the test; 21. Patients with a history of needle fainting, blood fainting or inability to tolerate venipuncture; 22. History of drug abuse, drug abuse and addiction; 23. Patients with obvious mental disorders, epilepsy and other persons without behavioral ability or cognitive ability; 24. History of malignant tumor or currently suffering from any malignant tumor; 25. Female subjects in pregnancy, lactation or pregnancy test (blood HCG test) positive; And the subjects have fertility or sperm / egg donation plans during the test period and within 60 days after the end of the test and cannot take effective physical contraceptive measures (effective contraceptive measures include abstinence, sterilization, intrauterine device, or diaphragm method stipulated by local laws); 26. An intervention clinical trial has been completed or withdrawn within 1 month before screening, or is currently undergoing an intervention clinical trial, or has participated in other medical research activities, which is not suitable to participate in this trial according to the judgment of the researcher; 27. The subjects may not be able to complete the test for other reasons or the researchers think they should not be included.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SY-009 capsules
3 capsules each time (3 test drugs), 3 times a day (oral administration before breakfast, lunch, dinner or with meals)

Locations

Country Name City State
China The Second Affiliated Hospital of Bengbu Medical College Bengbu Anhui
China Changsha Central Hospital Changsha Hunan
China Chengdu Fifth People's Hospital Chengdu Sichan
China The First Affiliated Hospital of Chongqing Medical University Chongqing Chongqing
China Affiliated Hospital of Hangzhou Normal University Hangzhou Zhejiang
China The Second Affiliated Hospital of Anhui Medical University Hefei Anhui
China The first hospital of Hebei Medical University Shijiazhuang Hebei

Sponsors (1)

Lead Sponsor Collaborator
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes of HbA1c compared with baseline at 12 weeks Changes of HbA1c in each dose group compared with baseline at 12 weeks of treatment 12 weeks
Secondary Changes of HbA1c compared with baseline at 8 weeks Changes of HbA1c in each dose group compared with baseline at 8 weeks of treatment 8 weeks
Secondary Changes of maximum blood glucose increase (0-180min) after breakfast compared with baseline at 12 weeks Changes of maximum blood glucose increase (0-180min) after breakfast in each dose group compared with baseline at 12 weeks of treatment 12 weeks
Secondary Proportion of subjects with HbA1c = 7% 8 weeks,12 weeks
Secondary Proportion of subjects with HbA1c = 6.5% 8 weeks,12 weeks
Secondary Changes of blood glucose at 2h after breakfast compared with baseline 12 weeks
Secondary Changes of insulin at 2h after breakfast compared with baseline 12 weeks
Secondary Changes of C-peptide at 2h after breakfast compared with baseline 12 weeks
Secondary Change of GLP-1 from baseline 2h after breakfast 12 weeks
Secondary Change of GIP from baseline 2h after breakfast 12 weeks
Secondary Change of mean fasting blood glucose from baseline 12 weeks
Secondary Change of fasting blood glucose from baseline 4 weeks,8 weeks,12 weeks
Secondary change of mean blood glucose value at 7 time points from baseline Based on SMPG test,the change of mean blood glucose value at 7 time points from baseline 4 weeks,8 weeks,12 weeks
Secondary Changes of blood glucose at 2h after meal compared with baseline Based on SMPG test,the Changes of blood glucose at 2h after meal (breakfast, lunch and dinner) compared with baseline 4 weeks,8 weeks,12 weeks
Secondary Changes in insulin resistance (HOMA-IR) from baseline 12 weeks
Secondary Islet of Langerhans ß Cellular function (HOMA- ß) Change from baseline 12 weeks
Secondary Blood drug concentration level 4 weeks,8 weeks,12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A